Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Akebia Therapeutics, Inc.

Get SEC filing alerts via email and in your feed for Akebia Therapeutics, Inc.

AKBA

Akebia Therapeutics, Inc.

About Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for kidney disease. Its core products include Vafseo, an oral treatment for anemia due to chronic kidney disease (CKD) in dialysis patients, and Auryxia, an oral medicine for hyperphosphatemia and iron deficiency anemia in CKD patients. Akebia leverages hypoxia-inducible factor (HIF) science and targets nephrology markets through direct sales and partnerships globally.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Akebia Therapeutics, Inc.

1
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports $9.1 Million Net Loss and 7% Revenue Decline for Q1 2026

Via official filing (AI summary) | 29 days ago | 0 comments

2
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports 49% Revenue Growth to $227.3 Million in 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports Net Income of $540,000 for Q3 2025, Significant Turnaround from Prior Year

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports 43% Revenue Growth to $62.5 Million for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports $6.1 Million Net Income and 76% Revenue Growth for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports 11% Revenue Decline and $69.4 Million Net Loss for 2024

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Akebia Therapeutics, Inc. Akebia Therapeutics Reports 11% Revenue Decline, Increased Net Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments